Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Phase 1 Not yet recruiting 120 enrolled University of Wisconsin, Madison Tiny Blue Dot Foundation · collab

RandomizedParallel-groupDouble-blindBasic science

Summary

This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the "trip") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months.

Timeline

Start: 2026-09
Primary completion: 2028-02
Completion: 2028-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Psilocybin	Other / unclassified	4 mg	Intravenous
Background	Clonidine	Other / unclassified	0.2 mg	Oral

Indications

No indication recorded.